Immuno-Oncology | Specialty

Dr. Spigel on FDA Approval of Pembrolizumab/Chemo Combo in NSCLC

May 11th 2017

David Spigel, MD, chief scientific officer, director, Lung Cancer Research Program, principal investigator, Sarah Cannon Research Institute, discusses the FDA approval of pembrolizumab plus chemotherapy as a frontline treatment for patients with non–small cell lung cancer (NSCLC).

FDA Approves Frontline Pembrolizumab Combo for NSCLC

May 11th 2017

The FDA has granted an accelerated approval to pembrolizumab for use in combination with pemetrexed plus carboplatin as a frontline treatment for patients with metastatic or advanced nonsquamous non–small cell lung cancer, regardless of PD-L1 expression.

Ritchie Reflects on Research Underway in Myeloproliferative Neoplasms

May 10th 2017

Ellen K. Ritchie, MD, highlights current and emerging novel treatments, and the possibility of using immunotherapy to treat patients with systemic mastocytosis, advanced symptomatic hypereosinoophic disorder, myelofibrosis, and chronic myelomonocytic leukemia

Atezolizumab Falls Short in Phase III Bladder Cancer Trial

May 10th 2017

Atezolizumab missed the phase III IMvigor211 trial’s primary endpoint of improving overall survival in the second-line setting for patients with locally advanced or metastatic urothelial carcinoma.

Dr. Siefker-Radtke on FDA Approval of Avelumab in Bladder Cancer

May 10th 2017

Arlene O. Siefker-Radtke, MD, associate professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, clinical co-leader, Bladder SPORE Executive Committee, discusses the FDA approval of avelumab for the treatment of patients with locally advanced or metastatic urothelial carcinoma whose disease has progressed after platinum-based therapy.

Dr. Slovin on the Challenges of Immunotherapy in Prostate Cancer

May 9th 2017

Susan F. Slovin, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the challenges of immunotherapy in prostate cancer.

FDA Approves Avelumab for Bladder Cancer

May 9th 2017

The FDA has granted an accelerated approval to the PD-L1 inhibitor avelumab (Bavencio) for the treatment of patients with locally advanced or metastatic urothelial carcinoma with disease progression during or following platinum-containing chemotherapy, or within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.

Expert Highlights Next Steps With Immunotherapy in NSCLC

May 6th 2017

Daniel Morgensztern, MD, discusses both the single-agent and combination immunotherapy data in non-small cell lung cancer and what researchers are poised to do next in the field.

Dr. Abou-Alfa on the Role of Immunotherapy in HCC

May 6th 2017

Ghassan K. Abou-Alfa, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the role of immunotherapy for patients with hepatocellular carcinoma (HCC).

Researchers Investigating TCR Therapy in NSCLC

May 6th 2017

Jeffrey P. Ward, MD, PhD, discusses the questions researchers still face about targeting the immune system and exactly what role T-cell receptor therapy could play in the treatment of patients with non-small cell lung cancer.

EU Approves Pembrolizumab for Hodgkin Lymphoma

May 5th 2017

The European Commission has approved pembrolizumab for the treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma who have progressed following autologous stem cell transplant and brentuximab vedotin, or who are transplant-ineligible and have failed brentuximab vedotin.

Dr. Hammers on Combination of Vaccines and Immune Checkpoint Inhibitors in RCC

May 5th 2017

Hans J. Hammers, MD, PhD, associate professor, Internal Medicine, UT Southwestern Medical Center, discusses the combination of vaccines and immune checkpoint inhibitors in the treatment of patients with renal cell carcinoma.

Emerging Therapies Show Promise in Head and Neck Cancer

May 4th 2017

Aarti Bhatia, MD, highlights the newer single agents and combination treatments being investigated for patients with head and neck cancer.

Dr. Strosberg on Challenges in the Treatment of Neuroendocrine Tumors

May 4th 2017

Jonathan R. Strosberg, MD, associate professor, Moffitt Cancer Center, discusses the challenges associated with treating neuroendocrine tumors (NETs).

Dr. Apolo on Avelumab for Metastatic Urothelial Carcinoma

May 4th 2017

Andrea B. Apolo, MD, medical oncologist at the National Cancer Institute, chief of the bladder cancer section of the Genitourinary Malignancies Branch, discusses avelumab (Bavencio) in patients with metastatic urothelial carcinoma from the phase Ib JAVELIN solid tumor trial.

Biomarker Advances Continue to Drive Progress in NSCLC

May 3rd 2017

Siddhartha Devarakonda, MD, discusses the importance of testing for molecular markers in NSCLC, rare mutations, and what work lies ahead for the field of lung cancer.

Lead CheckMate-040 Investigator Discusses Nivolumab in HCC

May 2nd 2017

Bruno Sangro, MD, PhD, discusses the CheckMate-040 data and the future of immuno-oncology agents in HCC.

Dr. Siefker-Radtke on FDA Approval of Durvalumab in Bladder Cancer

May 2nd 2017

Arlene O. Siefker-Radtke, MD, associate professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, clinical co-leader, Bladder SPORE Executive Committee, discusses the FDA approval of the PD-L1 inhibitor durvalumab for the treatment of patients with locally advanced or metastatic urothelial carcinoma whose disease has progressed on standard platinum‑based chemotherapy.

Expert Discusses Immunotherapy Potential in Ovarian Cancer

May 2nd 2017

Bradley J. Monk, MD, shares his insight on the potential of immunotherapy in ovarian cancer, as well as what promise it might hold in other gynecologic malignancies.

Dr. Gubens on Prevalence of EGFR/ALK/ROS1 and PD-L1 Expression in NSCLC

May 1st 2017

Matthew Gubens, MD, an assistant professor of thoracic oncology at the University of California San Francisco, discusses the prevalence of patients with non–small cell lung cancer (NSCLC) who harbor mutations in EGFR/ALK/ROS1 as well as PD-L1 expression.